Royal Bank of Canada
CYCN icon

Royal Bank of Canada’s Cyclerion Therapeutics CYCN Stock Holding History

Royal Bank of Canada’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-416
Closed -$1K – 6953
2024
Q2 		$1K Buy
416
+64
+18% +$182 ﹤0.01% 6802
2024
Q1 		$1K Buy
352
+22
+7% +$70 ﹤0.01% 6774
2023
Q4 		$1K Sell
330
-582
-64% -$1.68K ﹤0.01% 6909
2023
Q3 		$3K Buy
912
+73
+9% +$263 ﹤0.01% 6710
2023
Q2 		$3K Buy
839
+838
+83,800% +$4.34K ﹤0.01% 6779
2023
Q1 		$0 Hold
1
– – ﹤0.01% 7136
2022
Q4 		$0 Hold
1
– – ﹤0.01% 7304
2022
Q3 		$0 Hold
1
– – ﹤0.01% 7503
2022
Q2 		$0 Hold
1
– – ﹤0.01% 7421
2022
Q1 		$0 Hold
1
– – ﹤0.01% 7780
2021
Q4 		$0 Hold
1
– – ﹤0.01% 7682
2021
Q3 		$0 Sell
1
-243
-100% -$15.9K ﹤0.01% 7660
2021
Q2 		$19K Buy
244
+144
+144% +$9.02K ﹤0.01% 6584
2021
Q1 		$5K Sell
100
-32
-24% -$2.4K ﹤0.01% 7037
2020
Q4 		$8K Buy
132
+127
+2,540% +$8.66K ﹤0.01% 6470
2020
Q3 		$1K Hold
5
– – ﹤0.01% 6409
2020
Q2 		$0 Sell
5
-24
-83% -$2.01K ﹤0.01% 6668
2020
Q1 		$1K Buy
29
+25
+625% +$1.78K ﹤0.01% 6414
2019
Q4 		$0 Sell
4
-6
-60% -$560 ﹤0.01% 6861
2019
Q3 		$2K Hold
10
– – ﹤0.01% 6273
2019
Q2 		$2K Buy
+10
New +$2.83K ﹤0.01% 6559

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada's CYCN Position: Q3 2024 in Review

Royal Bank of Canada sold out of Cyclerion Therapeutics (CYCN) in Q3 2024, closing a stake of 416 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in CYCN in Q2 2019 and held it in 21 quarters. The position peaked at $19K in Q2 2021. 15 funds tracked by Wall St. Rank hold CYCN as of Q3 2024.

  • Royal Bank of Canada reported no remaining Cyclerion Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 416 Cyclerion Therapeutics shares in Q3 2024, an estimated $1K.
  • Royal Bank of Canada first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 21 quarters.
  • Royal Bank of Canada's Cyclerion Therapeutics position peaked at $19K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.